You are here:

Forthcoming Submission: inotuzumab ozogamicin (Besponsa)

Indication: As monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia. Adult patients with Philadelphia chromosome positive relapsed or refractory B cell precursor acute lymphoblastic leukaemia should have failed treated with at least 1 tyrosine kinase inhibitor.

Drug Details

Drug Name: inotuzumab ozogamicin (Besponsa)
Drug Manufacturer: Pfizer Ltd
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
5/03/2018
SMC Meeting Date: Q2 2018
Advice Due: Q2 2018

Back